Abstract · PDF, 63 KB
Estimate the value of adding abemaciclib to endocrine therapy for high-risk hormone receptor-positive and HER2-negative early breast cancer. Under the model assumptions, adding abemaciclib was unlikely to be cost-effective at the selected …
Keywords: abemaciclibbreast cancercost-effectiveness